Updates are available Correction dated 2020-06-12
Click to view Correction: https://doi.org/10.1038/s41577-020-0366-6
-
Authors
Risitano, Antonio M.
Mastellos, Dimitrios C. https://orcid.org/0000-0002-6634-3271
Huber-Lang, Markus
Yancopoulou, Despina
Garlanda, Cecilia
Ciceri, Fabio
Lambris, John D. https://orcid.org/0000-0002-9370-5776
- License Information
-
More Information
Article History
Accepted: 15 April 2020
First Online: 23 April 2020
Change Date: 12 June 2020
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41577-020-0366-6
Competing interests
: J.D.L. is the founder of Amyndas Pharmaceuticals and inventor of patents related to complement inhibitors, including a technology licensed to Apellis Pharmaceuticals. A.M.R. has received support from or served as an adviser for Biocryst, Achillion, Alexion, Alnylam, Amyndas, Apellis, Novartis, Roche, Omeros, Pfizer, Rapharma, Samsung and Sanofi. M.H.-L. holds a patent relating to C5a inhibition licensed to InflaRx. D.Y. is the Managing Director of Amyndas Pharmaceuticals. D.C.M., C.G. and F.C. declare no competing interests.
Free to read: This content has been made available to all.
